Reliability of FIB-4 Liver Fibrosis Screening in HIV Care

Clinical guidelines currently recommend a stepwise approach to monitoring liver health. Typically, clinicians start with FIB-4 liver fibrosis screening as an initial step before moving to more intensive diagnostic tests. However, a major multinational study has identified serious flaws in this strategy for people living with HIV (PWH). Although the FIB-4 index is easy to calculate, it often fails to detect significant liver damage accurately. This failure could potentially delay essential medical interventions for patients who appear low-risk on paper but suffer from underlying disease.

The Impact of Misclassification in Screening

The research evaluated nearly 5,000 people living with HIV across seven international centers. Investigators compared the results of FIB-4 scores against transient elastography (TE), which is the gold standard for non-invasive assessment. Consequently, they found that FIB-4 only showed modest accuracy for detecting significant fibrosis. Specifically, the index misclassified 36% of participants with significant fibrosis as being at low risk. This high rate of error suggests that many patients with liver stiffness measurements above 8 kPa remain undetected during routine checks. Furthermore, metabolic dysfunction-associated steatotic liver disease (MASLD) affected over 20% of the cohort, making accurate detection even more critical for this population.

Improving Prediction Beyond the FIB-4 Score

Clinicians often hope that HIV-specific factors, such as CD4 counts or viral load, might sharpen the accuracy of simple screening tools. Surprisingly, this study found that adding HIV-related data did not significantly improve risk prediction models. Instead, metabolic factors like body mass index (BMI) and diabetes remained the strongest indicators of liver health. Therefore, relying solely on FIB-4 could create a false sense of security in primary care settings. Practitioners should consider incorporating transient elastography earlier for high-risk patients to avoid missing advanced cases. In summary, while FIB-4 serves as a cost-effective starting point, its limitations in the HIV population require a more nuanced and aggressive diagnostic approach.

Frequently Asked Questions

Why is FIB-4 liver fibrosis screening often inaccurate for patients with HIV?

FIB-4 relies on age, platelet count, and liver enzymes, which may not fully reflect the unique inflammatory and metabolic environment in patients with HIV. Consequently, it may underestimate the severity of liver stiffness compared to specialized imaging like transient elastography.

Should all people with HIV undergo transient elastography?

While FIB-4 remains a common first step in many clinics, experts suggest using transient elastography (FibroScan) for those with existing metabolic risk factors. This approach ensures that clinicians do not miss the significant portion of fibrosis cases that a simple blood-based index might overlook.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Cinque F et al. FIB-4 fails to identify significant liver fibrosis in people with HIV: A large multinational screening study. Hepatology. 2026 May 01. doi: 10.1097/HEP.0000000000001773. PMID: 42065895.

Maurice JB et al. Diagnostic accuracy of non-invasive markers of fibrosis in HIV mono-infected patients with histologically confirmed NAFLD. bhiva.org.

Omeish HA et al. NOVEL INSIGHTS INTO THE ACCURACY OF FIB-4 AND FIBROSCAN SCORES COMPARED TO LIVER BIOPSY IN THE ASSESSMENT OF LIVER FIBROSIS IN PATIENTS WITH MASLD. Hepatology 2024; 80:S452.